Clinical trials: COVID-19 Booster
COVID-19
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with…
- Trial name
- NCT05343871
- Testing
- Sinovac, AZD1222, BNT162b2
- Where
- 2 sites in Brazil, Pakistan
- Volunteers
- 2,354 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
COVID-19
Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
This study will address specific questions concerning the additional protection of the AZ COVID-19 vaccine as a second booster dose in preventing severe COVID-19 outcomes (hospitalisation, ICU admission etc) and will provide data…
- Trial name
- REFORCO-B (NCT05697705)
- Testing
- ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen)
- Where
- Brazil
- Volunteers
- 188,814,085 people
- Sponsor
- AstraZeneca
COVID-19, Vaccines
Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up
This is a prospective randomized clinical trial evaluating how behaviorally-informed outreach text messages affect the take-up of bivalent COVID-19 booster.
- Trial name
- NCT05586204
- Testing
- Eligibility reminder, Link to a narrow set of vaccine venues, Link to a broad set of vaccine venues
- Where
- United States
- Volunteers
- 154,977 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine
Immunogenicity and Safety of Comvigen (Bivalent) Vaccine
This study will assess the safety, reactogenicity and immunogenicity of a single dose of Comvigen (Bivalent, ChulaCov19 BNA159.2) vaccine or BIVALENT Pfizer/BNT vaccine as a booster among healthy males and non-pregnant females…
- Conditions
- Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single Dose of COMVIGEN Vaccine, Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine
- Trial name
- NCT05930730
- Testing
- Comvigen (Bivalent, ChulaCov19 BNA159.2), BIVALENT Pfizer/BNT vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
VIDO has developed a vaccine called COVAC-1. The COVAC-1 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1.
- Trial name
- NCT05693272
- Testing
- COVAC-1
- Where
- 4 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
SARS-CoV-2, COVID-19 Vaccine
Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
This is a randomized, blinded, and dose escalation phase I trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT06167915
- Testing
- 30μg dose of LYB002V14, 60μg dose of LYB002V14
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Vaccine Refusal, COVID-19
Exploring the Effect of Video Interventions on Intentions for Continued COVID-19 Vaccination
While COVID-19 vaccine uptake has generally been high in Canada, with 83.4% of the total population having received the first two doses (i.e., primary series), additional "booster" uptake has been slower, especially among young…
- Trial name
- NCT05808413
- Testing
- Informational Video, Altruistic Video, Individualistic Video
- Where
- Canada
- Volunteers
- 3,567 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
COVID-19
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
- Trial name
- NCT06255626
- Testing
- CD40.RBDv vaccin (SARS-Cov2 Vaccin)
- Where
- 2 sites in France
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy People
Safety of UFRJvac, Trivalent COVID-19 Vaccine
Phase I study to evaluate the safety and immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19 vaccine.
- Trial name
- UFRJvac-1 (NCT06303635)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
COVID-19
A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults
This clinical trial aimed to gather safety and immunogenicity data in COVID-19 vaccine-experienced healthy adults. The main questions it aims to answer are: The neutralizing antibodies levels of bivalent mRNA vaccines…
- Trial name
- NCT05907044
- Testing
- RQ3013, RQ3025, RQ3027
- Where
- China
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Yunnan University
COVID-19
Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
This Phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of PepGNP-COVID19, a synthetic nanoparticle-based, T cell-priming peptide vaccine against SARS-CoV-2, when administered as a booster dose in…
- Trial name
- NCT07183709
- Testing
- PepGNP-COVID19, Sterile Water for Injection
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.
This clinical trial is a single-blind, randomised study to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccine (Pfizer-BioNTech) as booster dose in adults, who…
- Trial name
- NCT05265065
- Testing
- Tozinameran - Standard Dose, Tozinameran - Fractional Dose
- Where
- Mongolia
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
COVID-19 Pandemic
Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05158855
- Testing
- Bacillus subtilis spore extract
- Where
- Macau
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
COVID-19 (Healthy Volunteers)
Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
This is randomized, placebo-controlled, observer-blinded, multi-center study to assess safety, reactogenicity and immunogenicity of booster vaccination of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted…
- Trial name
- NCT05175950
- Testing
- SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, Normal saline
- Where
- 9 sites in South Korea
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
COVID-19, Vaccine Reaction
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2 vaccines than healthy population.
- Conditions
- COVID-19, Vaccine Reaction, Liver Diseases
- Trial name
- NMCIDCHESS2201 (NCT05204602)
- Where
- 19 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
COVID-19 Recurrent, Lung Cancer
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients…
- Conditions
- COVID-19 Recurrent, Lung Cancer, Vaccination, Antibody
- Trial name
- NCT06168032
- Testing
- Any Chinese government-recommended COVID-19 booster vaccine
- Where
- China
- Volunteers
- 1,224 people
- Sponsor
- Peking Union Medical College Hospital
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.
- Trial name
- NCT05305573
- Testing
- COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
- Where
- 7 sites in Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Rheumatoid Arthritis
MTX Hold During Covid-19 Booster
To investigate the effect of MTX discontinuation for 1 week on vaccination response to Covid-19 booster vaccination in RA patients.
- Trial name
- NCT05313061
- Testing
- MTX
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital